Ascendis Pharma to Present New Clinical Data on Rare Endocrine Disorders at ENDO 2026

COPENHAGEN, Denmark — June 2026 — Ascendis Pharma has announced that it will present significant new findings from its rare endocrine disease research programs during ENDO 2026, the annual scientific meeting of the Endocrine Society scheduled to take place in Chicago, Illinois, from June 13 to June 16, 2026. The company plans to share data from multiple clinical studies involving patients with hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency, reinforcing its commitment to advancing innovative treatments for rare endocrine disorders.

Expanding the Understanding of Rare Endocrine Diseases

Rare endocrine disorders affect thousands of patients worldwide and often require lifelong treatment and monitoring. Ascendis Pharma has focused its research efforts on developing therapies that address the underlying causes of these conditions rather than merely managing symptoms. Through its proprietary TransCon technology platform, the company aims to improve treatment outcomes and quality of life for patients living with complex hormonal disorders.

The presentations at ENDO 2026 will feature both long-term safety and efficacy results from ongoing clinical development programs and new analyses that provide deeper insight into patient outcomes. According to company executives, the upcoming data demonstrate the continued progress of Ascendis Pharma’s endocrinology portfolio and its potential to transform standards of care for several rare diseases.

Key Oral Presentations Scheduled at ENDO 2026

Final Phase 3 PaTHway Trial Results for Hypoparathyroidism

One of the most anticipated presentations will focus on palopegteriparatide (TransCon PTH), an investigational hormone replacement therapy designed for adults with hypoparathyroidism. Researchers will present the final results from the Phase 3 PaTHway clinical trial, which evaluated the therapy's long-term effectiveness and safety.

Hypoparathyroidism is a rare endocrine condition characterized by insufficient production of parathyroid hormone, resulting in low blood calcium levels and elevated phosphorus concentrations. Existing treatments often rely on calcium and vitamin D supplementation, which may not fully address the disease burden. The PaTHway study aims to determine whether hormone replacement therapy can offer a more comprehensive treatment approach.

Promising Results for Children with Achondroplasia

Another major presentation will highlight 52-week findings from the Phase 2 COACH trial, evaluating the combination of navepegritide (TransCon CNP) and lonapegsomatropin (TransCon hGH) in children with achondroplasia.

Achondroplasia is the most common form of skeletal dysplasia and is associated with impaired bone growth and a range of medical complications. Researchers believe that combining therapies targeting different biological pathways may offer enhanced benefits for growth and skeletal development. The latest study results are expected to provide important evidence regarding the long-term potential of this treatment strategy.

Additional Research Featured Through Poster Presentations

Improved Work Productivity in Adults with Chronic Hypoparathyroidism

Ascendis Pharma will also present findings demonstrating how palopegteriparatide may positively influence workplace performance and daily functioning among adults with chronic hypoparathyroidism. The analysis is based on 156-week data collected during the PaTHway trial.

The results examine measures such as work productivity, job performance, and overall functioning, helping researchers better understand how effective treatment may impact patients beyond traditional clinical endpoints.

Global Prevalence of Chronic Hypoparathyroidism

A separate poster presentation will provide updated estimates of the worldwide prevalence of chronic hypoparathyroidism. The research combines data from numerous published studies using systematic review and meta-analysis methodologies.

Understanding disease prevalence is critical for healthcare planning, patient identification, and resource allocation. The findings could help healthcare providers and policymakers better estimate the number of individuals affected by this rare endocrine disorder globally.

Real-World Growth Hormone Deficiency Registry Data

Researchers will also share insights from the SkybriGHt Registry, which tracks patients receiving lonapegsomatropin therapy for pediatric growth hormone deficiency. The analysis includes data from the first 100 enrolled patients who have completed two years of follow-up.

The registry is designed to provide real-world evidence regarding treatment effectiveness and long-term safety outside the controlled environment of clinical trials. Such information is increasingly valuable for physicians making treatment decisions in routine clinical practice.

Company Leadership Emphasizes Commitment to Scientific Advancement

Ascendis Pharma leadership has emphasized the importance of sharing robust clinical evidence through peer-reviewed scientific forums. Company executives believe that transparent presentation of long-term data is essential for advancing patient care and supporting informed treatment decisions among healthcare professionals.

The organization continues to invest heavily in research aimed at addressing significant unmet needs within endocrinology. By leveraging its TransCon technology platform, Ascendis Pharma seeks to create therapies that provide sustained hormone exposure while potentially improving convenience and effectiveness compared with traditional treatment approaches.

The Growing Importance of ENDO 2026

ENDO is recognized as one of the world's leading scientific meetings dedicated to hormone research and endocrine medicine. The conference attracts endocrinologists, researchers, healthcare professionals, and industry leaders from around the globe to discuss emerging discoveries and treatment innovations.

The 2026 meeting in Chicago is expected to showcase groundbreaking developments across numerous areas of endocrinology, including rare endocrine disorders, metabolic diseases, growth disorders, and hormone replacement therapies. Ascendis Pharma’s presentations are anticipated to be among the key highlights of the event due to the growing interest in novel treatments for rare diseases.

Potential Impact on Patients and Healthcare Providers

The data being presented at ENDO 2026 could have important implications for patients living with hypoparathyroidism, achondroplasia, and growth hormone deficiency. Positive long-term outcomes may support broader adoption of innovative therapeutic approaches and encourage continued research into rare endocrine conditions.

For healthcare professionals, the findings provide valuable evidence regarding treatment durability, safety, quality-of-life outcomes, and real-world effectiveness. These insights may ultimately contribute to improved patient management strategies and more personalized approaches to care.

Looking Ahead

As rare endocrine disease research continues to evolve, the upcoming presentations from Ascendis Pharma underscore the industry's ongoing effort to develop more effective and patient-centered therapies. With multiple studies reporting long-term outcomes and real-world data, ENDO 2026 is expected to provide a comprehensive view of recent advances in endocrine medicine.

The company's expanding endocrinology pipeline reflects a broader trend toward targeted treatments designed to address the biological mechanisms underlying rare diseases. As additional clinical data emerge, healthcare professionals and patients alike will be watching closely to see how these innovations shape the future of endocrine care.

#SlimScan #GrowthStocks #CANSLIM